Literature DB >> 11771667

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

Francis H Glorieux1, Leanne M Ward, Frank Rauch, Ljiljana Lalic, Peter J Roughley, Rose Travers.   

Abstract

Osteogenesis imperfecta (OI) is a heritable disease of bone in which the hallmark is bone fragility. Usually, the disorder is divided into four groups on clinical grounds. We previously described a group of patients initially classified with OI type IV who had a discrete phenotype including hyperplastic callus formation without evidence of mutations in type I collagen. We called that disease entity OI type V. In this study, we describe another group of 8 patients initially diagnosed with OI type IV who share unique, common characteristics. We propose to name this disorder "OI type VI." Fractures were first documented between 4 and 18 months of age. Patients with OI type VI sustained more frequent fractures than patients with OI type IV. Sclerae were white or faintly blue and dentinogenesis imperfecta was uniformly absent. All patients had vertebral compression fractures. No patients showed radiological signs of rickets. Lumbar spine areal bone mineral density (aBMD) was low and similar to age-matched patients with OI type IV. Serum alkaline phosphatase levels were elevated compared with age-matched patients with type IV OI (409 +/- 145 U/liter vs. 295 +/- 95 U/liter; p < 0.03 by t-test). Other biochemical parameters of bone and mineral metabolism were within the reference range. Mutation screening of the coding regions and exon/intron boundaries of both collagen type I genes did not reveal any mutations, and type I collagen protein analyses were normal. Qualitative histology of iliac crest bone biopsy specimens showed an absence of the birefringent pattern of normal lamellar bone under polarized light, often with a "fish-scale" pattern. Quantitative histomorphometry revealed thin cortices, hyperosteoidosis, and a prolonged mineralization lag time in the presence of a decreased mineral apposition rate. We conclude that type VI OI is a moderate to severe form of brittle bone disease with accumulation of osteoid due to a mineralization defect, in the absence of a disturbance of mineral metabolism. The underlying genetic defect remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11771667     DOI: 10.1359/jbmr.2002.17.1.30

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  88 in total

1.  Modeling the benefits of pamidronate in children with osteogenesis imperfecta.

Authors:  Robert Lindsay
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year.

Authors:  Joanne Ruck; Noémi Dahan-Oliel; Kathleen Montpetit; Frank Rauch; François Fassier
Journal:  J Child Orthop       Date:  2011-05-08       Impact factor: 1.548

3.  Case report: osteogenesis imperfecta Elusive cause of fractures.

Authors:  Elizabeth L Strevel; Alexandra Papaioannou; Jonathan D Adachi; Marty McNamara
Journal:  Can Fam Physician       Date:  2005-12       Impact factor: 3.275

Review 4.  Unexplained fractures in infancy: looking for fragile bones.

Authors:  Nick Bishop; Alan Sprigg; Ann Dalton
Journal:  Arch Dis Child       Date:  2007-03       Impact factor: 3.791

Review 5.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

Review 6.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

7.  [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].

Authors:  O Semler; C Land; E Schönau
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 8.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

9.  Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix.

Authors:  Joanna Witecka; Aleksandra M Auguściak-Duma; Anna Kruczek; Anna Szydło; Marta Lesiak; Maria Krzak; Jacek J Pietrzyk; Minna Männikkö; Aleksander L Sieroń
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

10.  Clinical and radiological manifestations of osteogenesis imperfecta type V.

Authors:  Dong Yeon Lee; Tae-Joon Cho; In Ho Choi; Chin Youb Chung; Won Joon Yoo; Ji Hyung Kim; Yong Koo Park
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.